What changed for Thyroid Cancer
A plain English summary of what recently moved in the public data Voxsanity tracks for Thyroid Cancer. Updated from government registries. Not medical advice.
How to read these changes: every figure on this page is the difference between two snapshots of what Voxsanity had tracked on each date. Voxsanity only began taking daily snapshots in July 2026 and is still ingesting the public registries, so a rise here is mostly our own coverage expanding rather than new research appearing. Read it as our tracked coverage growing, not as a claim about real-world research changing this fast: it overstates how much actually changed.
Comparing the two most recent snapshots, 27 July 2026 and 28 July 2026.
- Trials recruiting worldwide 215 to 214 (-1)
- Late-stage (Phase 3) trials 13 to 12 (-1)
- Trials on record 1,125 to 1,124 (-1)
Newly subsidised on the PBS
No medicines were newly subsidised on the PBS for Thyroid Cancer in July 2026. Voxsanity tracks 3 PBS-subsidised medicines for this condition; none of them was listed for the first time this month.
Source: Pharmaceutical Benefits Scheme (PBS), © Commonwealth of Australia. Data used and redistributed under permission; not modified from its original wording where displayed verbatim.
Past updates
Tracking began in July 2026. Month on month changes will appear here once a second month of data has been recorded. Until then, the comparison above shows the most recent movement.
Recent trend
Weekly, most recent weeks (fills out to a monthly trend as history grows).
Recent trial results
The 30 most recent of 63 trials tracked for Thyroid Cancer that have reported results to a public registry.
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
-
NCT06054178 · results posted 20 May 2026
According to the results reported on ClinicalTrials.gov, this trial enrolled 8 participants, all of whom completed the study — none dropped out. The trial was looking at whether a dye called fluorescein sodium, given during surgery, could help surgeons see facial nerves more clearly. To do this, the researchers measured how well the dye's glow lined up with two other ways of identifying nerves: electrical stimulation (a standard surgical tool that confirms nerve location) and the surgeon's own eye under normal white light. They also measured how brightly the nerve glowed compared to the surrou...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT04439292 · results posted 19 May 2026
According to the results reported on ClinicalTrials.gov, this trial (NCT04439292) enrolled 44 participants who received a combination of two medicines — dabrafenib and trametinib. All 44 participants were in a single treatment group, meaning there was no comparison or placebo group. Of the 44 who started, 36 were confirmed eligible, treated, and had their mutation status confirmed. The trial was primarily measuring how many participants' tumours shrank or disappeared (called the "objective response rate"), and secondarily tracking how long participants went without their disease getting worse....
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT03157128 · results posted 16 April 2026
According to the results reported on ClinicalTrials.gov, this trial (NCT03157128) tested a medicine called selpercatinib in people with certain cancers that carry specific genetic changes known as RET alterations — including RET fusions and RET mutations — in cancers such as thyroid cancer and other solid tumours. The trial ran in two stages: a Phase 1 dose-finding stage, where 857 participants across ten different dose groups tested doses ranging from 20 mg up to 240 mg; and a Phase 2 stage, where 857 further participants were enrolled across six groups based on their cancer type and treatmen...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT03899792 · results posted 6 January 2026
According to the results reported on ClinicalTrials.gov, this trial tested a drug called LOXO-292 (also known as selpercatinib) in children and young people with certain types of cancer. The trial had two phases. In Phase 1, three participants took part to check whether the drug caused any serious dose-related side effects at the planned dose level. Phase 2 then enrolled 36 participants across three groups: 15 with medullary thyroid cancer (MTC), 15 with papillary thyroid cancer (PTC), and 6 with other cancer types. The trial was primarily measuring whether the dose caused particular side effe...
-
NCT03109847 · results posted 11 December 2025
According to the results reported on ClinicalTrials.gov, this trial compared metformin hydrochloride (a medication) against a placebo (a dummy treatment with no active ingredient) in people who had undergone surgery and radioactive iodine treatment, likely for thyroid cancer. A total of 13 people took part — 6 in the metformin group and 7 in the placebo group. Of these, 12 completed the study (5 in the metformin group and 7 in the placebo group), with one person in the metformin group not completing it. The trial was measuring changes in red blood cell counts, a profile of tiny particles found...
-
NCT03914300 · results posted 31 October 2025
According to the results reported on ClinicalTrials.gov, this trial enrolled 11 participants, all of whom received a combination of three medicines: cabozantinib s-malate, nivolumab, and ipilimumab. Ten participants completed the study, and one did not. The trial was measuring how often tumours shrank or disappeared within the first six months of treatment (called the "objective response rate"), as well as tracking how long any response lasted, how long participants lived without their disease getting worse, and how long participants survived overall. The reported data shows that the objectiv...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT04985604 · results posted 2 October 2025
According to the results reported on ClinicalTrials.gov, this trial enrolled 23 people across two groups: 8 participants with melanoma (the Melanoma Cohort) and 15 participants with various other cancer types (the Tissue Agnostic Cohort). The trial was primarily measuring the **overall response rate** — that is, the proportion of participants whose tumours showed a meaningful shrinkage or disappearance according to standard scanning criteria, as judged by the treating doctor. The trial also tracked how long any such response lasted, how long participants went without their disease worsening, a...
-
NCT01896479 · results posted 2 September 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT01896479) enrolled 247 people in total — 123 in a group taking a 60 mg daily dose of a drug called cabozantinib, and 124 in a group taking a 140 mg daily dose of the same drug. All participants received at least one dose. The trial was primarily measuring how long participants went without their disease getting worse (called "progression-free survival"), and also looked at how many participants' tumours shrank or disappeared by a meaningful amount (called the "objective response rate"). The reported data shows that, when...
Read the full trial page · View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT01723202 · results posted 24 August 2025
According to the results reported on ClinicalTrials.gov, this trial enrolled 53 people in total — 26 in one group receiving a drug called dabrafenib on its own (Arm A), and 27 in another group receiving dabrafenib combined with a second drug called trametinib (Arm B). Some participants in Arm A later switched ("crossed over") to the combination treatment. The trial was measuring how often tumours responded to treatment, how long it took for the disease to progress, how long participants lived, and what side effects and dose changes occurred. The reported data shows that, for the primary measu...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT04284774 · results posted 3 June 2025
According to the results reported on ClinicalTrials.gov, this trial enrolled 5 children and young people (referred to as paediatric patients) who received a drug called tipifarnib. The trial was designed to measure how many participants' tumours shrank or disappeared (known as an "objective response"), how long participants went without their disease getting worse (called "progression-free survival"), and what proportion experienced serious side effects. All 5 participants are recorded as not having completed the study, and none are recorded as having completed it — the data does not explain t...
Read the full trial page · View reported results on ClinicalTrials.gov ↗
-
NCT04129411 · results posted 20 May 2025
According to the results reported on ClinicalTrials.gov, this trial involved 5 participants, all of whom completed the study. The trial was looking at radiofrequency ablation (RFA) — a procedure that uses heat to treat thyroid nodules (small growths on the thyroid gland in the neck). The main thing being measured was whether the nodules got smaller after the procedure. The trial also tracked several other things, including pain during the procedure, whether nearby lymph nodes became enlarged, whether the cancer spread to other parts of the body, whether there were any complications at the trea...
-
NCT04579757 · results posted 8 May 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT04579757) enrolled 87 people in total across two phases. The first phase tested two different doses of a combination of two medicines — surufatinib and tislelizumab — in 12 people, to see how the body tolerated the treatment and to find a suitable dose. The second phase then enrolled 75 people across seven groups, each made up of participants with a different type of cancer, including colorectal cancer, certain lung cancers, cancers of the digestive and hormonal system (neuroendocrine tumours), stomach cancer, a soft-tissu...
-
NCT04420689 · results posted 8 May 2025
According to the results reported on ClinicalTrials.gov, this trial enrolled 27 people in total, split across seven groups. The first five groups (3 people each) received different doses of a drug called ALM-488 — 100 mg, 200 mg, 400 mg, 500 mg, or 600 mg — to help find the right dose. The remaining two groups (6 people each) tested different timing windows between receiving ALM-488 and a follow-up procedure. The trial was primarily measuring whether participants experienced any unwanted side effects that were linked to ALM-488, using a standard medical checklist. It also tracked how quickly t...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT04281875 · results posted 17 October 2024
According to the results reported on ClinicalTrials.gov, this trial (NCT04281875) enrolled 160 adults who were undergoing thyroid surgery (total thyroidectomy). Participants were divided into two equal groups of 80: one group whose surgeon used a special near-infrared light-based detection technology (called NIRAF) alongside normal eyesight to locate the parathyroid glands (small glands near the thyroid that help control calcium levels), and one group where surgeons relied on normal eyesight alone. All 160 participants completed the study. The main thing being measured was how many parathyroid...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT02383927 · results posted 11 July 2024
According to the results reported on ClinicalTrials.gov, this trial (NCT02383927) looked at a drug called tipifarnib across 63 people in total, divided into four groups: Cohort 1 (13 people), Cohort 2/Stage 1 (10 people), Cohort 2/Stage 2 (30 people), and Cohort 3 (10 people). The trial was measuring how many participants' tumours shrank or disappeared (called the objective response rate, or ORR), as well as tracking things like how long people went without their disease getting worse, how long any tumour shrinkage lasted, and how long participants survived overall. It is worth noting that the...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT04782856 · results posted 14 June 2024
According to the results reported on ClinicalTrials.gov, this trial (NCT04782856) enrolled 13 people in total — 7 in a "Single Therapy" group and 6 in a "Combination Therapy" group. All 7 people in the Single Therapy group completed the study, while 5 of the 6 in the Combination Therapy group completed it (one person did not finish). The trial was measuring short-term changes in weight, the number of calories the body burns over 24 hours (called energy expenditure), cholesterol levels in the blood, and quality of life related to thyroid conditions. The reported data shows the following number...
-
NCT04211337 · results posted 13 June 2024
According to the results reported on ClinicalTrials.gov, this trial (NCT04211337) compared two treatment groups in people with a specific type of cancer: 193 participants received selpercatinib (Group A) and 98 participants received either cabozantinib or vandetanib (Group B). The trial was primarily measuring how long participants went without their disease getting worse or dying — a timeframe called "progression-free survival." It also looked at a number of secondary measures, including how many participants' tumours shrank or disappeared, how long those responses lasted, and how long partic...
Read the full trial page · View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT03215095 · results posted 22 March 2024
According to the results reported on ClinicalTrials.gov, this trial enrolled 11 participants, all of whom completed the study. The trial looked at a combination treatment — radioiodine (a type of radiation therapy commonly used for thyroid conditions) together with a drug called durvalumab (also known as Medi4736). The main thing researchers were measuring was the number of participants who experienced what are called "dose-limiting toxicities" — that is, serious side effects severe enough to limit or stop the treatment dose. A secondary measure looked at how participants' tumours responded, u...
-
NCT02244463 · results posted 12 January 2024
According to the results reported on ClinicalTrials.gov, this trial (NCT02244463) enrolled 59 people across two stages. The first stage (Phase I) involved 19 participants split into smaller groups to test different doses of the study treatment, with the goal of finding the highest dose that could be given without too many serious side effects — this is called the Maximum Tolerated Dose (MTD). The second stage (Phase II) enrolled 40 participants split into two groups based on their type of thyroid cancer: 18 people with anaplastic thyroid cancer (ATC, a fast-growing form) and 22 people with dif...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT01709435 · results posted 21 December 2023
According to the results reported on ClinicalTrials.gov, this trial studied a drug called cabozantinib s-malate in children and young people with certain solid tumours. A total of 41 participants were enrolled across six different dosing groups, which were part of three study sections (called Part A, Part B, and Part PK). The trial was mainly trying to find the highest dose that could be given without too many serious side effects — known as the maximum tolerated dose — and also looked at how the body processed the drug and how tumours responded. The reported data shows that the recommended d...
-
NCT02973997 · results posted 24 October 2023
According to the results reported on ClinicalTrials.gov, this trial (NCT02973997) enrolled two separate groups of participants — 30 people in Cohort 1 and 25 people in Cohort 2, for a total of 55 participants. The two groups appear to have had different types of thyroid cancer, and the trial was measuring how often participants' tumours showed a response to the combination of pembrolizumab and lenvatinib, as well as tracking survival and side effects over time. Of the 55 people who started the trial, only 10 completed it (8 from Cohort 1 and 2 from Cohort 2), with the remainder not completing...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT03690388 · results posted 18 May 2023
According to the results reported on ClinicalTrials.gov, this trial (NCT03690388) enrolled 187 people in total — 125 received a medicine called cabozantinib and 62 received a placebo (a dummy treatment with no active ingredient). The trial was measuring two main things: how long participants went without their disease getting worse (called "progression-free survival"), and how many participants had their disease visibly shrink or disappear (called "objective response rate"). The reported data shows that for progression-free survival — the time until the disease showed signs of growing or the...
Read the full trial page · View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT00936858 · results posted 28 September 2021
According to the results reported on ClinicalTrials.gov, 50 people took part in this trial, all assigned to receive a drug called RAD001 (also known as everolimus). Ten of those participants had a specific type of thyroid cancer called medullary thyroid cancer. None of the 50 participants were recorded as having completed the trial. The trial was measuring how long people lived without their cancer growing (called progression-free survival), how many people's tumours shrank or disappeared (objective response rate), how long people lived overall, and — for the medullary thyroid cancer group onl...
-
NCT02393690 · results posted 3 August 2021
According to the results reported on ClinicalTrials.gov, this trial involved 58 people with a type of thyroid cancer that had come back or spread. Participants were split into two groups: 28 people received a drug called selumetinib combined with radioactive iodine treatment, and 30 people received a placebo (a dummy pill with no active ingredient) combined with the same radioactive iodine treatment. The trial was primarily measuring how many people in each group showed a meaningful shrinkage or disappearance of their cancer at the 6-month mark. The reported data shows that at 6 months, 7 out...
-
NCT03174925 · results posted 8 July 2021
According to the results reported on ClinicalTrials.gov, this trial enrolled 55 participants, with 52 completing the study and 3 not completing it. The trial was looking at thyroid nodules — small lumps found in the thyroid gland in the neck — and whether a scanning technique called elastography could measure how stiff those nodules are. Elastography works by assessing how firm or hard tissue is, which researchers wanted to compare against whether each nodule turned out to be cancerous, non-cancerous (benign), or uncertain (indeterminate). Cancer status was determined either by a fine needle a...
-
NCT01885195 · results posted 21 February 2021
According to the results reported on ClinicalTrials.gov, this trial enrolled 110 participants who all received a drug called binimetinib (also known as MEK162). The trial was designed to measure how many participants — across different cancer types including solid tumours, multiple myeloma (a blood cancer), and acute myeloid leukaemia (AML, another blood cancer) — showed a response or their disease stayed stable for at least 16 weeks. It is noted that none of the 110 participants were recorded as having formally "completed" the study, with all 110 listed under "not completed." The reported da...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT02702388 · results posted 11 January 2021
According to the results reported on ClinicalTrials.gov, this trial (NCT02702388) involved 152 people in total — 75 received a 24 mg daily dose of lenvatinib and 77 received an 18 mg daily dose. The trial was measuring two main things up to 24 weeks: how many participants had their tumours shrink or disappear (called the "objective response rate"), and how many experienced serious side effects (graded as severe or worse) during that same period. It also tracked how long it took before the disease got worse or participants passed away, and other safety-related measures. The reported data shows...
Read the full trial page · View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT02138214 · results posted 21 December 2020
According to the results reported on ClinicalTrials.gov, this trial (NCT02138214) enrolled 90 people across three groups of 30 each. The groups were: people who had thyroid surgery without a procedure called central neck dissection (Arm I, "no CND"), people who had the surgery with central neck dissection (Arm II, "CND"), and a third standard-of-care group (Arm III, "SOC"). The trial was measuring things related to calcium levels and parathyroid hormone (a chemical that helps control calcium) in the body after surgery — specifically how often low calcium-related problems occurred, how much cal...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT02946918 · results posted 1 December 2020
According to the results reported on ClinicalTrials.gov, this trial compared two forms of thyroid medication — tablets and gelcaps — in a small group of people being treated for a thyroid condition. A total of 14 people started the trial (6 in the tablets group and 8 in the gelcaps group), though only 10 completed it (5 in each group). The trial was measuring whether each form of the medication could bring a hormone level in the blood — called TSH (thyroid stimulating hormone) — into a specific target range over 18 weeks, as well as looking at how many dose adjustments were needed, how partici...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT02432274 · results posted 17 September 2020
According to the results reported on ClinicalTrials.gov, this trial (NCT02432274) looked at a medicine called lenvatinib in children and young people with certain solid tumour cancers. The trial was organised into several groups: some participants received lenvatinib on its own at different doses to find the best dose to use (Cohorts 1 and 2), while others received it combined with two chemotherapy medicines — etoposide and ifosfamide — again at different doses (Cohorts 3A and 3B). In total, 97 participants started the trial across all groups, and 97 were treated. The trial measured things lik...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
See all 63 reported results for Thyroid Cancer
These are the results as reported to the registry, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
What is coming
AI generated pipeline summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to NIH funding data, a substantial amount of public research investment is currently directed toward thyroid cancer, and that investment is rising year on year. This is an encouraging signal for patients, as growing funding generally means more researchers are working to better understand the disease and explore new approaches. While funding does not guarantee treatments will reach patie...
See the full Thyroid Cancer page
Not medical advice. Voxsanity republishes public government health data in plain English. These figures describe research and registry activity, not the suitability of any treatment for any person. Trial status can change; always verify current status directly with the trial site and confirm Australian availability with your doctor.